Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SuperGen Planning Dacogen NDA Submission For Myelodysplastic Syndrome In Third Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

The company plans to begin the fast-track decitabine NDA submission in the second quarter and complete submission in the third quarter. Pharmion’s MDS agent could come to market before then – Vidaza (azacitadine) has a user fee date of June 29.

You may also be interested in...

MGI Pharma Adding Three Compounds in Three Deals

Mergers with Aesgen and Zycos and a licensing deal with Supergen give MGI pipeline products that dovetail with the sales needs of its existing anti-emetic Aloxi.

Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint

The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts